ArticleJournal of medical case reports2026
Delayed diagnosis of ertapenem-induced delirium in an elderly patient with multimorbidity and septic shock: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErtapenem, a broad-spectrum carbapenem antibiotic, is commonly used for treating infections such as septic shock. However, its neurotoxic side effects, especially in elderly patients with multiple comorbidities and renal impairment, are rarely reported. This case report highlights a rare but clinically significant adverse effect of ertapenem-delirium-underscoring its importance in medical literature. CASE PRESENTATION: We report the case of a 76-year-old Chinese male patient admitted with septic shock secondary to community-acquired pneumonia. Initial treatment with ertapenem showed improvement, but the patient developed delirium on the third day of therapy. Comprehensive diagnostic evaluations ruled out common causes of cognitive impairment, leading to the suspicion of ertapenem-induced neurotoxicity. Upon discontinuation of the drug, the patient's mental state gradually improved, with full cognitive recovery within days. The clear temporal association between ertapenem administration and the onset of delirium, alongside the rapid improvement after discontinuation, strongly supports a causal link.
conclusionThis case underscores the importance of recognizing drug-induced delirium in elderly patients receiving ertapenem, particularly those with renal dysfunction or multiple comorbidities. By reporting this case, we aim to raise awareness of this rare but significant adverse effect, emphasizing the need for vigilance in monitoring neuropsychiatric symptoms in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.